MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive MomentumGlobeNewsWire • 03/31/26
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy ProgramsGlobeNewsWire • 03/17/26
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric CancersGlobeNewsWire • 03/10/26
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone SymposiaGlobeNewsWire • 02/04/26
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host DiseaseGlobeNewsWire • 01/08/26
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid TumorsGlobeNewsWire • 11/20/25
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025GlobeNewsWire • 11/07/25
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of DirectorsGlobeNewsWire • 09/29/25
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MAGlobeNewsWire • 09/25/25
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal DevelopmentGlobeNewsWire • 09/18/25
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 ResultsGlobeNewsWire • 08/14/25
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial ReportGlobeNewsWire • 07/31/25
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell TherapyGlobeNewsWire • 07/15/25
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant PatientsGlobeNewsWire • 06/02/25
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic ProgressGlobeNewsWire • 05/15/25
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business ProgressGlobeNewsWire • 03/18/25